How will US pharma manufacturing be reshaped by the Trump administration?

A perfect Storm for US Drug Manufacturing as FDA Changes, Trade Wars and M&A Surge Collide

"There's optimism… but the challenges aren't day to day - it can be minute to minute," warns Gil Roth, President of the Pharma and Biopharma Outsourcing Association (PBOA), describing a pharmaceutical manufacturing sector facing unprecedented change in 2025.

Gil Roth brings deep expertise in pharmaceutical policy and manufacturing legislation, having launched PBOA in 2014 as an essential bridge between contract manufacturers and government stakeholders.

In the latest PharmaSource podcast episode, Gil shares detailed insights into how the new administration's trade policies and leadership changes will likely create both challenges and opportunities for US pharmaceutical manufacturing.

Read the full article

Join Gil Roth and other industry experts at CDMO Live 2025